Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00125)
Name
Chlorpropamide
Synonyms    Click to Show/Hide the Synonyms of This API
chlorpropamide; 94-20-2; Chloropropamide; Diabinese; Chlorpropamid; Diabenese; Glucamide; Meldian; Chlorodiabina; Chloronase; Diabeneza; Diabetoral; Adiaben; Catanil; Diabaril; Dynalase; Insulase; Melitase; Diabechlor; Diabenal; Mellinese; Millinese; Asucrol; Glisema; Oradian; Diabet-Pages; Diamel Ex; 4-chloro-N-(propylcarbamoyl)benzenesulfonamide; Clorpropamide; Diabexan; Prodiaben; 1-(4-Chlorophenylsulfonyl)-3-propylurea; Chlorpropamidum; Clorpropamida; 1-(p-Chlorobenzenesulfonyl)-3-propylurea; 1-Propyl-3-(p-chlorobenzenesulfonyl)urea; N-(4-Chlorophenylsulfonyl)-N'-propylurea; N-(p-Chlorobenzenesulfonyl)-N'-propylurea; N-Propyl-N'-(p-chlorobenzenesulfonyl)urea; 4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide; 1-(4-chlorophenyl)sulfonyl-3-propylurea; 1-(p-Chlorophenylsulfonyl)-3-propylurea; 1-p-Chlorophenyl-3-(propylsulfonyl)urea; NCI-C01752; 4-Chloro-N-((propylamino)carbonyl)benzenesulfonamide; UNII-WTM2C3IL2X; N-Propyl-N'-p-chlorphenylsulfonylcarbamide; n-Propyl-N'-p-chlorophenylsulfonylcarbamide; NSC 44634; Benzenesulfonamide, 4-chloro-N-[(propylamino)carbonyl]-; U-9818; 4-Chloro-4-((propylamino)carbonyl)benzenesulfonamide; Benzenesulfonamide, 4-chloro-N-((propylamino)carbonyl)-; Clorpropamid; MFCD00079004; WTM2C3IL2X; CHEMBL498; MLS000028395; CHEBI:3650; Bioglumin; Insogen; Urea, 1-((p-chlorophenyl)sulfonyl)-3-propyl-; NSC626720; CAS-94-20-2; NCGC00015216-11; Chlorporpamide; SMR000058364; Clorpropamide [DCIT]; DSSTox_CID_322; chlorpropamide, alpha-form; Clorpropamide [Italian]; 1-(4-chloro-benzenesulfonyl)-3-n-propyl-urea; Urea, 1-[(p-chlorophenyl)sulfonyl]-3-propyl-; chlorpropamide, epsilon-form; DSSTox_RID_75512; DSSTox_GSID_20322; chlorpropamide, epsilon`-form; Chlorpropamidum [INN-Latin]; Clorpropamida [INN-Spanish]; Diabinese (TN); CCRIS 155; 1-(p-Chlorobenzensulfonyl)-3-propylurea; HSDB 2051; 1-((p-Chlorophenyl)sulfonyl)-3-propylurea; 4-chloro-n-(propylaminocarbonyl)benzenesulfonamide; SR-01000000060; 4-chloro-N-((propylaminocarbonyl)benzenesulfonamide; N-[(4-chlorophenyl)sulfonyl](propylamino)carboxamide; EINECS 202-314-5; U-3818; NSC 626720; BRN 2218363; 1-[(4-chlorobenzene)sulfonyl]-3-propylurea; Urea, 1-((p-chloropenyl)sulfonyl)-3-propyl-; Prestwick_684; Chlorpropamide [USP:INN:BAN:JAN]; Chlorpropamide B.P.; Spectrum_000144; ACMC-209rqj; 1-(4-chlorobenzenesulfonyl)-3-propylurea; 1-(4-chlorophenyl)sulfonyl-3-propyl-urea; Opera_ID_359; ADENYLOSUCCINICACID; Prestwick0_000323; Prestwick1_000323; Prestwick2_000323; Prestwick3_000323; Spectrum2_000089; Spectrum3_000347; Spectrum4_000284; Spectrum5_000719; WLN: GR DSWMVM3; Lopac-C-1290; chlorpropamide, delta-form; C 1290; Lopac0_000229; SCHEMBL23947; BSPBio_000325; BSPBio_002013; KBioGR_000808; KBioGR_002273; KBioSS_000624; KBioSS_002274; MLS001148665; DivK1c_000513; SPECTRUM1500185; SPBio_000018; SPBio_002246; BPBio1_000359; GTPL6801; DTXSID9020322; HMS501J15; KBio1_000513; KBio2_000624; KBio2_002273; KBio2_003192; KBio2_004841; KBio2_005760; KBio2_007409; KBio3_001233; KBio3_002753; Chlorpropamide (JP17/USP/INN); cMAP_000007; NINDS_000513; HMS1569A07; HMS1920M05; HMS2091E08; HMS2096A07; HMS2233L19; HMS3259A17; HMS3260N19; HMS3373D09; HMS3428C03; HMS3652L03; HMS3713A07; Pharmakon1600-01500185; BCP09162; HY-B1429; NSC44634; ZINC1530599; Tox21_110102; Tox21_201391; Tox21_302789; Tox21_500229; ANW-40217; BDBM50344965; CCG-38905; NSC-44634; NSC756690; SBB056923; STK857458; AKOS001482739; Tox21_110102_1; CS-4917; DB00672; KS-5316; LP00229; MCULE-3261763364; NC00503; NSC-626720; NSC-756690; SDCCGSBI-0050217.P005; IDI1_000513; MRF-0000539; NCGC00015216-01; NCGC00015216-02; NCGC00015216-03; NCGC00015216-04; NCGC00015216-05; NCGC00015216-06; NCGC00015216-07; NCGC00015216-08; NCGC00015216-09; NCGC00015216-10; NCGC00015216-12; NCGC00015216-13; NCGC00015216-14; NCGC00015216-17; NCGC00015216-18; NCGC00015216-23; NCGC00021451-03; NCGC00021451-04; NCGC00021451-05; NCGC00021451-06; NCGC00021451-07; NCGC00021451-08; NCGC00256414-01; NCGC00258942-01; NCGC00260914-01; AK116029; SY052508; SBI-0050217.P004; AB00051944; Chlorpropamide, analytical standard, >=97%; EU-0100229; ST50412138; SW196839-3; A16447; D00271; Urea, 1-propyl-3-(p-chloro-benzenesulfonyl)-; AB00051944_16; AB00051944_17; Q1075324; SR-01000000060-2; SR-01000000060-4; SR-01000000060-6; W-100205; 4-Chloro-N-[(propylamino)-carbonyl]benzenesulfonamide; BRD-K97746869-001-05-6; BRD-K97746869-001-15-5; 1-Chloro-4-(([(propylamino)carbonyl]amino)sulfonyl)benzene #; Chlorpropamide, European Pharmacopoeia (EP) Reference Standard; Chlorpropamide, United States Pharmacopeia (USP) Reference Standard; Chlorpropamide, Pharmaceutical Secondary Standard; Certified Reference Material
Clinical Status
Approved
Disease Indication Diabetes mellitus ICD-11: 5A10 [1]
PubChem CID
2727
Formula
C10H13ClN2O3S
Canonical SMILES
CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl
InChI
1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)
InChIKey
RKWGIWYCVPQPMF-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=2727"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 276.74 Topological Polar Surface Area 83.6
XlogP 2.3 Complexity 345
Heavy Atom Count 17 Rotatable Bond Count 4
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 3
Full List of Drug Formulations (DFMs) Containing This API
          Chlorpropamide 100 mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Glycine; Sodium lauryl sulfate; Calcium carbonate; D&c yellow no. 10; Fd&c blue no. 1; Magnesium stearate; Croscarmellose sodium; Silicon dioxide; Cellulose, microcrystalline
                   Dosage Form Oral Tablet
                   Company Mylan Pharamceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
FD&C blue no. 1 DIG Info Solute carrier SLCO2B1 (Ki = 13 uM) [2]
Sodium lauryl sulfate DIG Info Solute carrier SLCO2B1 (Ki = 1.98 uM) [2]
Calcium carbonate DIG Info Carbonic anhydrase IX (Ki = 8600 nM) [3]
Quinoline yellow WS DIG Info Estrogen receptor alpha (IC50 = 18 uM) [4]
Aminoethanoic acid DIG Info Glycine type-1 transporter (IC50 = 31600 nM) [5]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [6]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [6]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [6]
          Chlorpropamide 250 mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Glycine; Sodium lauryl sulfate; Calcium carbonate; D&c yellow no. 10; Fd&c blue no. 1; Magnesium stearate; Croscarmellose sodium; Silicon dioxide; Cellulose, microcrystalline
                   Dosage Form Oral Tablet
                   Company Mylan Pharamceuticals; PD-Rx Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
FD&C blue no. 1 DIG Info Solute carrier SLCO2B1 (Ki = 13 uM) [2]
Sodium lauryl sulfate DIG Info Solute carrier SLCO2B1 (Ki = 1.98 uM) [2]
Calcium carbonate DIG Info Carbonic anhydrase IX (Ki = 8600 nM) [3]
Quinoline yellow WS DIG Info Estrogen receptor alpha (IC50 = 18 uM) [4]
Aminoethanoic acid DIG Info Glycine type-1 transporter (IC50 = 31600 nM) [5]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [6]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [6]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [6]
References
1 FDA label for approved chlorpropamide from the official website of the U.S. Food and Drug Administration.
2 Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives. Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):16009-16018.
3 Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbonate. Bioorg Med Chem Lett. 2005 Feb 1; 15(3):567-71.
4 The activities of drug inactive ingredients on biological targets. Science. 2020 Jul 24;369(6502):403-413.
5 Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: development of a potent and CNS penetrant [3.1.0]-based lead. Bioorg Med Chem Lett. 2014 Feb 15; 24(4):1067-70.
6 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.